RDSM – Rede de Documentação sobre Saúde em Moçambique

Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses

Chissumba, Raquel Matavele; Luciano, Abílio; Namalango, Eduardo; Bauer, Asli; Bhatt, Nilesh; Wharen, Britta; Nilsson, Charlotta; Geldmacher, Christof; Scarlatti, Gabriella; Jani, Ilesh; Kastens, Luc.

Immunobiol., Suppl; 223 (12), 2018

Little is known about regulatory CD4 T cells (Tregs) in the context of HIV vaccines. Tregs can be differentiated into resting (FoxP3+CD45RA+ - rTregs), activated (FoxP3HighCD45RA- - aTregs) and memory (FoxP3LowCD45RA- - mTregs). Tregs, as CD4 T cells, are also frequent targets for HIV infection. We studi...

AIDS Vaccines/immunology, Antibodies, Neutralizing/immunology, CD4 Lymphocyte Count, Cytokines/biosynthesis, HIV Antibodies/immunology, HIV Infections/prevention & control, HIV Infections/virology, HIV-1/immunology, HIV-1/genetics, Mozambique, CD8-Positive T-Lymphocytes/immunology, T-Lymphocytes, Regulatory/metabolism, Vaccines, DNA/immunology, Vaccines, DNA/genetics

Fulltext

Optimizing the immunogenicity of HIV primeboost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

PLOS ONE; 13 (6), 2018

Although there has been a decline in the number of new human immunodeficiency virus (HIV) infections over the years, millions of people continue to be exposed and infected [1]. More than 200 HIV vaccine phase I and II, and 6 efficacy trials have been conducted [2, 3]. The RV144 Thai trial is the only tri...